

[Vinblastine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01CA01](#)

Indication

Kaposi sarcoma of unspecified primary site ICD11 code: [2C27.Z](#)

INN

Vinblastine

Medicine type

Chemical agent

List type

Complementary

Additional notes

For intravenous use only

Formulations

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) ; 10 mg per 10 mL in vial (vinblastine sulfate)

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Vinblastine](#)

[DrugBank](#)

[Vinblastine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new formulation of vinblastine IV injection (10 mg/10 mL) to the EML and EMLc.